We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 235

Intellectual property weekly abstracts bulletin Week of July 14

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 17 2014

Allianz Asset Management of America L.P. (“AAMA”) and Allianz Global Investors of America L.P. (“AGIA”) appealed two decisions of the Trade-marks

Order of prohibition overturned on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 16 2014

The issue to be determined by the Court of Appeal related to whether the allegation of lack of utility was justified. The Court of Appeal began by

Clinical studies exempted from public use in allegation of anticipation

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

His is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations. The Court began by noting that it had issued an Order of

Final injunction permits existing patients to continue to receive infringing medicine

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision

Claim seeking punitive and exemplary damages denied as part of section 8 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

His is a case relating to the drug Viagra. This was an appeal from an order of the Federal Court which dismissed an appeal from an order of a

Competition Bureau discontinues inquiry into alleged anti-competitive conduct by Alcon Canada Inc.

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

The Competition Bureau has discontinued its inquiry into whether Alcon Canada Inc. (Alcon) had engaged in anti-competitive conduct contrary to the

Court bifurcates determination of Start Date for section 8 action

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 12 2014

Health Canada has published: Data requirements for switching medicinal ingredients from prescription to non-prescription status

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 5 2014

The amendments to the Patent Rules and Trade-marks Regulations affecting both patent and trade-mark agents came into effect on May 1, 2014. The

Oder of prohibition issues no promise to treatment in humans or reduced side effects was found

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is